Trending NewsTrending NewsNASDAQ:TEM Tempus AI (TEM) Stock Price, News & Analysis $67.61 -0.01 (-0.01%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$67.68 +0.08 (+0.11%) As of 05:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Tempus AI Stock (NASDAQ:TEM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tempus AI alerts:Sign Up Key Stats Today's Range$62.67▼$68.1450-Day Range$49.36▼$85.0852-Week Range$40.77▼$93.38Volume4.68 million shsAverage Volume6.38 million shsMarket Capitalization$12.20 billionP/E RatioN/ADividend YieldN/APrice Target$72.37Consensus RatingHold Company Overview Tempus AI, Inc. is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies. Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data. Tempus also provides data and analytics services to biopharmaceutical companies and other life sciences organizations. Tempus was founded in 2015 by Eric Lefkofsky, who serves as its chief executive officer. Headquartered in Chicago, the company primarily serves healthcare providers, researchers and life sciences companies in the United States. Tempus became a publicly traded company on the Nasdaq under the symbol TEM in 2024.AI Generated. May Contain Errors. Read More Tempus AI Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreTEM MarketRank™: 2.572238725355 of 5 starsTempus AI scored higher than 51% of companies evaluated by MarketBeat, and ranked 497th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingHold Consensus RatingTempus AI has received a consensus rating of Hold. The company's average rating score is 2.41, and is based on no strong buy ratings, 11 buy ratings, 9 hold ratings, and 2 sell ratings.Upside/DownsideThe consensus price target for Tempus AI is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageTempus AI has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tempus AI's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tempus AI are expected to grow in the coming year, from ($1.43) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tempus AI is -46.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tempus AI is -46.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTempus AI has a P/B Ratio of 24.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tempus AI's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted18.38% of the float of Tempus AI has been sold short.Short Interest Ratio / Days to CoverTempus AI has a short interest ratio ("days to cover") of 3.22, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tempus AI has recently decreased by 10.48%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTempus AI does not currently pay a dividend.Dividend GrowthTempus AI does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.49 News SentimentTempus AI has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Tempus AI this week, compared to 9 articles on an average week.Search InterestOnly 33 people have searched for TEM on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows27 people have added Tempus AI to their MarketBeat watchlist in the last 30 days. This is an increase of 170% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tempus AI insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $80,397,564.00 in company stock.Percentage Held by Insiders24.26% of the stock of Tempus AI is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions24.22% of the stock of Tempus AI is held by institutions.Read more about Tempus AI's insider trading history. Receive TEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tempus AI and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TEM Stock News HeadlinesThrowback to Palantir vs ServiceNow vs Tempus AI in specialist AIOctober 25 at 5:49 PM | msn.comPathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other ...October 24 at 3:03 PM | markets.ft.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets. | Weiss Ratings (Ad)Tempus AI expands collaboration with Bristol MyersOctober 23 at 7:09 PM | tipranks.comTempus AI, Inc. Enters Into Multi-Year Agreement With Bristol Myers Squibb To License Multimodal Oncology DataOctober 23 at 7:09 PM | marketscreener.comMPathos AI partners with Bristol Myers Squibb and Tempus AI to accelerate medical researchOctober 23 at 2:09 PM | marketscreener.comMTempus AI: Less Risky Than When I Said BuyOctober 23 at 2:09 PM | seekingalpha.comThe AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning (TEM)AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.October 19, 2026 | marketbeat.comSee More Headlines TEM Stock Analysis - Frequently Asked Questions How have TEM shares performed this year? Tempus AI's stock was trading at $59.05 at the beginning of the year. Since then, TEM stock has increased by 14.5% and is now trading at $67.61. How were Tempus AI's earnings last quarter? Tempus AI, Inc. (NASDAQ:TEM) announced its quarterly earnings data on Thursday, July, 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.10. Tempus AI's revenue was up 21.6% compared to the same quarter last year. Read the conference call transcript. When did Tempus AI IPO? Tempus AI (TEM) raised $400 million in an initial public offering (IPO) on Wednesday, June 12th 2024. The company issued 11,100,000 shares at a price of $35.00-$37.00 per share. Who are Tempus AI's major shareholders? Tempus AI's top institutional investors include Washington Trust Advisors Inc. (0.07%), Diversify Advisory Services LLC (0.04%), Fagan Associates Inc. (0.04%) and Titleist Asset Management LLC (0.03%). Insiders that own company stock include Bradley A Keywell, Andrew Polovin, James William Rogers, Eric P Lefkofsky, Erik Phelps, Ryan M Bartolucci, Nadja West, David R Epstein, Jennifer A Doudna and Ryan Fukushima. View institutional ownership trends. How do I buy shares of Tempus AI? Shares of TEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tempus AI own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tempus AI investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Tesla (TSLA), Broadcom (AVGO), Micron Technology (MU) and SoundHound AI (SOUN). Company Calendar Last Earnings7/30/2026Today10/25/2026Next Earnings (Confirmed)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TEM's financial health is in the Green zone, according to TradeSmith. TEM has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNASDAQ:TEM Previous SymbolNASDAQ:TEM CIK1717115 Webwww.tempus.com Phone800-976-5448FaxN/AEmployees3,800Year Founded2015Price Target and Rating Average Price Target for Tempus AI$72.37 High Price Target$100.00 Low Price Target$35.00 Potential Upside/Downside+7.0%Consensus RatingHold Rating Score (0-4)2.41 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($1.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$245.03 million Net Margins-17.77% Pretax Margin-17.62% Return on Equity-50.28% Return on Assets-10.33% Debt Debt-to-Equity Ratio3.06 Current Ratio3.30 Quick Ratio3.16 Sales & Book Value Annual Sales$1.27 billion Price / Sales9.59 Cash FlowN/A Price / Cash FlowN/A Book Value$2.76 per share Price / Book24.50Miscellaneous Outstanding Shares180,430,000Free Float136,661,000Market Cap$12.20 billion OptionableOptionable Beta3.54 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:TEM) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredForget the AI predictions. Look at the incomeAI predictions are everywhere, but Tim Plaehn is focused on something concrete: income. He's found a small ...Investors Alley | SponsoredFinally… options made simpleIan Cooper once believed successful options trading meant endless chart-watching, complex strategies, and big ...TradeWins | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...Paradigm Press | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempus AI, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempus AI With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
